MediPharm Labs AI Stock Analysis
Want to see TSE:LABS full AI Analyst Report?
MediPharm Labs (LABS) AI Stock Analysis
MediPharm Labs
(TSX:LABS)
The score is primarily constrained by persistent losses, negative cash flow, and weak technical positioning. Positive recent earnings-call developments—including improved profitability, revenue growth, cost reductions, and a low-debt balance sheet—provide meaningful support but do not yet offset the company’s high-risk turnaround profile.
MediPharm Labs (LABS) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 20.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 128.79K
- Price to Earnings (P/E)
- -6.0
- Beta (1Y)
- 0.72
- Revenue Growth
- -6.74%
- EPS Growth
- 43.54%
- Country
- Canada
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
MediPharm Labs Business Overview & Revenue Model
Company Description
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across C...
MediPharm Labs Earnings Call Summary
The call was predominantly positive. MediPharm reported 18% sequential revenue growth, strong international medical performance, positive net income for the second consecutive quarter, positive adjusted EBITDA for the third consecutive quarter, lower operating expenses and a strong balance sheet. These achievements outweighed the stated challenges in Australia, the impact of Veterans Affairs Canada reimbursement changes, the year-to-date revenue decline versus the prior year and the sequential gross margin decrease.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said Australia’s recovery will take time, but the actions taken are believed to better align the portfolio with evolving patient demand and position the business for improved performance over time. The Q1 restructuring initiatives are expected to generate more than $1 million in annualized savings. MediPharm intends to continue expanding in regulated medical markets, pursue future commercialization of its metered dose inhaler in the U.K. and European Union, and evaluate selective M&A opportunities that meet its return thresholds. Brazil remains an attractive longer-term growth opportunity, while the LiBBY study may lead to potential additional clinical development or regulatory pathways and/or strategic partnerships.
MediPharm Labs Financial Statement Overview
Summary
Financial performance is weak overall: the income statement score is 32.0 and cash flow score is 27.0, reflecting ongoing losses and negative operating and free cash flow. The balance sheet is a relative strength, scoring 61.0 because of minimal debt and substantial equity, but continued losses are eroding that cushion.
Income Statement
32NegativeBalance Sheet
61PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.46M | 45.12M | 41.96M | 33.06M | 22.12M | 21.71M |
| Gross Profit | 14.22M | 13.97M | 12.80M | 5.86M | -1.91M | -15.25M |
| EBITDA | -3.50M | -6.54M | -7.52M | -10.48M | -27.09M | -38.55M |
| Net Income | -4.97M | -8.27M | -10.69M | -13.08M | -29.98M | -54.80M |
Balance Sheet | ||||||
| Total Assets | 45.99M | 45.74M | 53.73M | 63.94M | 65.50M | 92.36M |
| Cash, Cash Equivalents and Short-Term Investments | 9.85M | 10.81M | 11.69M | 17.98M | 24.14M | 34.11M |
| Total Debt | 421.00K | 201.00K | 388.00K | 2.29M | 632.00K | 216.00K |
| Total Liabilities | 10.56M | 9.93M | 10.55M | 10.93M | 9.49M | 9.21M |
| Stockholders Equity | 35.43M | 35.81M | 43.18M | 53.01M | 56.01M | 83.15M |
Cash Flow | ||||||
| Free Cash Flow | -960.00K | -5.60M | -5.01M | -12.81M | -16.93M | -14.00M |
| Operating Cash Flow | -897.00K | -5.50M | -4.86M | -12.34M | -16.07M | -13.21M |
| Investing Cash Flow | 412.00K | 4.62M | 413.00K | 6.87M | 5.16M | 35.00K |
| Financing Cash Flow | -37.00K | -18.00K | -1.85M | -368.00K | 796.00K | 27.80M |
MediPharm Labs Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LABS, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LABS.
MediPharm Labs Peers Comparison
Overall Rating
TSE:ROMJ58Neutral- TSE:LABS48.9Neutral
TSE:AVCN44Neutral
TSE:OILS43Neutral
TSE:PCLO42Neutral
TSE:INNO41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:ROMJ | 58Neutral | CAD 27.03M | -16.26 | -4.00% | ― | 16.66% | -1007.41% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -6.03 | -13.79% | ― | -6.74% | 43.54% |
| TSE:AVCN | 44Neutral | CAD 11.42M | -2.62 | -108.44% | ― | -0.23% | -142.54% |
| TSE:OILS | 43Neutral | CAD 3.40M | -1.75 | -43.92% | ― | -18.30% | -397.37% |
| TSE:PCLO | 42Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:INNO | 41Neutral | CAD 8.19M | -6.15 | -19.37% | ― | -19.20% | 42.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | 0.00 | 0.00% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.00 | 6.67% | |
| TSE:OILS | Nextleaf Solutions | 0.02 | -0.04 | -63.64% | |
| TSE:ROMJ | Rubicon Organics | 0.40 | -0.10 | -20.20% | |
| TSE:AVCN | Avicanna Inc | 0.09 | -0.14 | -62.22% | |
| TSE:INNO | Innocan Pharma Corporation | 1.82 | -13.88 | -88.41% |
MediPharm Labs Corporate Events
MediPharm Labs Clears Key European Regulatory Hurdle for Cannabis Inhaler
PositiveMediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids, including proprietary metered-dose inhalers containing THC, CBD, CBN and CBG. Its platform targets medicinal-cannabis markets in Canada, Australia, the United Ki...
MediPharm Labs Schedules Third-Quarter 2026 Results Release
NeutralMediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids, including purified cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. Its regulated manufacturing capabilities and intern...
MediPharm Labs Appoints Greg Hunter as CEO and Director
PositiveMediPharm Labs appointed Greg Hunter as chief executive officer and a director effective November 4, 2026, after he served as interim CEO since January while remaining chief financial officer. He will retain CFO responsibilities until a successor is...
MediPharm Labs Enters Panama with CBD Inhaler as Latin American Medical Cannabis Market Accelerates
PositiveMediPharm Labs has entered Panama’s medical cannabis market with its first commercial shipment of CBD metered-dose inhalers to local partner Adeiwa Pharma, expanding an international footprint that already spans more than 10 countries. The smoke-free...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026